102 related articles for article (PubMed ID: 17415380)
1. Lentiviral vector neutral endopeptidase gene transfer suppresses prostate cancer tumor growth.
Horiguchi A; Zheng R; Goodman OB; Shen R; Guan H; Hersh LB; Nanus DM
Cancer Gene Ther; 2007 Jun; 14(6):583-9. PubMed ID: 17415380
[TBL] [Abstract][Full Text] [Related]
2. Neutral endopeptidase inhibits prostate cancer tumorigenesis by reducing FGF-2-mediated angiogenesis.
Horiguchi A; Chen DY; Goodman OB; Zheng R; Shen R; Guan H; Hersh LB; Nanus DM
Prostate Cancer Prostatic Dis; 2008; 11(1):79-87. PubMed ID: 17563767
[TBL] [Abstract][Full Text] [Related]
3. Loss of neutral endopeptidase and activation of protein kinase B (Akt) is associated with prostate cancer progression.
Osman I; Dai J; Mikhail M; Navarro D; Taneja SS; Lee P; Christos P; Shen R; Nanus DM
Cancer; 2006 Dec; 107(11):2628-36. PubMed ID: 17083125
[TBL] [Abstract][Full Text] [Related]
4. Tumor-suppressive effects of neutral endopeptidase in androgen-independent prostate cancer cells.
Dai J; Shen R; Sumitomo M; Goldberg JS; Geng Y; Navarro D; Xu S; Koutcher JA; Garzotto M; Powell CT; Nanus DM
Clin Cancer Res; 2001 May; 7(5):1370-7. PubMed ID: 11350908
[TBL] [Abstract][Full Text] [Related]
5. [*OPCML gene transferred by recombinant lentiviruses in vitro and its inhibition to ovarian cancer cells].
Yao DS; Li L; Garson K; Vanderhyden BC
Zhonghua Fu Chan Ke Za Zhi; 2006 May; 41(5):333-8. PubMed ID: 16762191
[TBL] [Abstract][Full Text] [Related]
6. Targeting of prostate cancer cells by a cytotoxic lentiviral vector containing a prostate stem cell antigen (PSCA) promoter.
Petrigliano FA; Virk MS; Liu N; Sugiyama O; Yu D; Lieberman JR
Prostate; 2009 Sep; 69(13):1422-34. PubMed ID: 19489029
[TBL] [Abstract][Full Text] [Related]
7. Neuropeptide-stimulated cell migration in prostate cancer cells is mediated by RhoA kinase signaling and inhibited by neutral endopeptidase.
Zheng R; Iwase A; Shen R; Goodman OB; Sugimoto N; Takuwa Y; Lerner DJ; Nanus DM
Oncogene; 2006 Sep; 25(44):5942-52. PubMed ID: 16652149
[TBL] [Abstract][Full Text] [Related]
8. Regression of prostate cancer xenografts by a lentiviral vector specifically expressing diphtheria toxin A.
Zheng JY; Chen D; Chan J; Yu D; Ko E; Pang S
Cancer Gene Ther; 2003 Oct; 10(10):764-70. PubMed ID: 14502229
[TBL] [Abstract][Full Text] [Related]
9. Intratumoral gene delivery of anti-cathepsin L single-chain variable fragment by lentiviral vector inhibits tumor progression induced by human melanoma cells.
Frade R; Rousselet N; Jean D
Cancer Gene Ther; 2008 Sep; 15(9):591-604. PubMed ID: 18617916
[TBL] [Abstract][Full Text] [Related]
10. Involvement of neutral endopeptidase in neoplastic progression.
Sumitomo M; Shen R; Nanus DM
Biochim Biophys Acta; 2005 Aug; 1751(1):52-9. PubMed ID: 16054017
[TBL] [Abstract][Full Text] [Related]
11. Effects of recombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo.
Bunn PA; Helfrich BA; Brenner DG; Chan DC; Dykes DJ; Cohen AJ; Miller YE
Clin Cancer Res; 1998 Nov; 4(11):2849-58. PubMed ID: 9829752
[TBL] [Abstract][Full Text] [Related]
12. Neutral endopeptidase protein expression and prognosis in localized prostate cancer.
Osman I; Yee H; Taneja SS; Levinson B; Zeleniuch-Jacquotte A; Chang C; Nobert C; Nanus DM
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4096-100. PubMed ID: 15217945
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of laryngeal cancer cell invasion and growth with lentiviral-vector delivered short hairpin RNA targeting human MMP-9 gene.
Sun Y; Liu M; Yang B; Lu J; Li B
Cancer Invest; 2008 Dec; 26(10):984-9. PubMed ID: 19093256
[TBL] [Abstract][Full Text] [Related]
14. Smad3 is overexpressed in advanced human prostate cancer and necessary for progressive growth of prostate cancer cells in nude mice.
Lu S; Lee J; Revelo M; Wang X; Lu S; Dong Z
Clin Cancer Res; 2007 Oct; 13(19):5692-702. PubMed ID: 17908958
[TBL] [Abstract][Full Text] [Related]
15. Endogenous bone morphogenetic protein-7 controls the motility of prostate cancer cells through regulation of bone morphogenetic protein antagonists.
Ye L; Lewis-Russell JM; Kynaston H; Jiang WG
J Urol; 2007 Sep; 178(3 Pt 1):1086-91. PubMed ID: 17644136
[TBL] [Abstract][Full Text] [Related]
16. Neutral endopeptidase 24.11/CD10 suppresses progressive potential in ovarian carcinoma in vitro and in vivo.
Kajiyama H; Shibata K; Terauchi M; Morita T; Ino K; Mizutani S; Kikkawa F
Clin Cancer Res; 2005 Mar; 11(5):1798-808. PubMed ID: 15756002
[TBL] [Abstract][Full Text] [Related]
17. The effect of a novel botanical agent TBS-101 on invasive prostate cancer in animal models.
Evans S; Dizeyi N; Abrahamsson PA; Persson J
Anticancer Res; 2009 Oct; 29(10):3917-24. PubMed ID: 19846929
[TBL] [Abstract][Full Text] [Related]
18. The effects of lentiviral gene therapy with bone morphogenetic protein-2-producing bone marrow cells on spinal fusion in rats.
Miyazaki M; Sugiyama O; Tow B; Zou J; Morishita Y; Wei F; Napoli A; Sintuu C; Lieberman JR; Wang JC
J Spinal Disord Tech; 2008 Jul; 21(5):372-9. PubMed ID: 18600149
[TBL] [Abstract][Full Text] [Related]
19. Negative regulation of NEP expression by hypoxia.
Mitra R; Chao OS; Nanus DM; Goodman OB
Prostate; 2013 May; 73(7):706-14. PubMed ID: 23138928
[TBL] [Abstract][Full Text] [Related]
20. Adenoviral neutral endopeptidase gene delivery in combination with paclitaxel for the treatment of prostate cancer.
Iida K; Zheng R; Shen R; Nanus DM
Int J Oncol; 2012 Oct; 41(4):1192-8. PubMed ID: 22895534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
